When it comes to innovation and the marketing mix, some say the
healthcare industry lags behind. As a healthcare marketing solutions
company, we work feverishly to keep our finger on the pulse of innovation and
creative solutions for our clients. MedTera understands that innovation isn’t
spurred solely from looking inward in healthcare. We look outward to leaders
of marketing innovation from all industries. This is healthcare marketing in
the 21st century. We "deliver beyond the fold" by integrating dimensional
and digital solutions into multi-wave marketing campaigns that capture the
attention of your key targets to engage and elicit response. We assist in marketing your brand by turning medical facts into creative ideas.
A new study has shown that direct-to-consumer pharmaceutical marketing campaigns are effective in swaying perceptions about comparative products. Marketers who are planning an integrated campaign should use this information to tailor their advertisements to optimize consumer preference.
As the healthcare industry changes to adapt to patient and population needs, more physicians are becoming part of a hospital or corporation. With fewer doctors practicing independently, there are significant changes in their incentives and how pharmaceutical and medical device companies should be targeting them.
Email is often an essential part of an integrated marketing campaign, but there are a number of small mistakes that can compromise an email's effectiveness. Healthcare marketers who are using email as part of their company's strategy should double-check to ensure they are not making these four common errors.
To make a company stand out in the world of digital advertisements, marketers should focus their efforts on information relevance rather than creative presentation. Research has shown that companies that use simple, tailored utilities and ads are the most successful.
The U.S. Food and Drug Administration recently released its final ruling on the exclusivity period of fixed-dose combination drugs. The agency decided that all new treatments that contain more than one drug will be eligible for five years of marketing exclusivity, starting with products approved on or after Oct. 10, 2014.